Johnson & Johnson Acquires Intra-Cellular Therapies, Expands Mental Health Portfolio

Johnson & Johnson has finalized its acquisition of Intra-Cellular Therapies, Inc., bringing the mental health drug CAPLYTA® (lumateperone) into its portfolio. CAPLYTA® is the only FDA-approved treatment for depressive episodes associated with bipolar I and II disorders as both a monotherapy and adjunctive therapy. It’s also approved for schizophrenia in adults. A supplemental application for its use in major depressive disorder is under FDA review.

This acquisition is expected to strengthen J&J’s neuroscience capabilities and support its long-term sales growth with CAPLYTA® projected to exceed $5 billion in peak annual sales. The deal also includes ITI-1284, a promising drug in Phase 2 trials for generalized anxiety disorder and Alzheimer’s-related psychosis.

Johnson & Johnson estimates an additional $0.7 billion in sales for 2025 due to this acquisition, although a slight EPS dilution of $0.25 is expected for the year. Integration of Intra-Cellular Therapies into J&J Innovative Medicine has already begun, and its stock has ceased trading on NASDAQ.

The announcement includes safety warnings and prescribing information for CAPLYTA®, as well as forward-looking statements that highlight potential risks and uncertainties involved in the acquisition and product development.